Multistate programme to reduce catheter-associated infections in intensive care units with elevated infection rates.


Journal

BMJ quality & safety
ISSN: 2044-5423
Titre abrégé: BMJ Qual Saf
Pays: England
ID NLM: 101546984

Informations de publication

Date de publication:
05 2020
Historique:
received: 11 01 2019
revised: 04 10 2019
accepted: 13 10 2019
pubmed: 9 1 2020
medline: 20 1 2021
entrez: 9 1 2020
Statut: ppublish

Résumé

Preventing central line-associated bloodstream infection (CLABSI) and catheter-associated urinary tract infection (CAUTI) remains challenging in intensive care units (ICUs). The Agency for Healthcare Research and Quality Safety Program for ICUs aimed to reduce CLABSI and CAUTI in units with elevated rates. Invited hospitals had at least one adult ICU with elevated CLABSI or CAUTI rates, defined by a positive cumulative attributable difference metric (CAD >0) in the Centers for Disease Control and Prevention's Targeted Assessment for Prevention strategy. This externally facilitated programme implemented by a national project team and state hospital associations included on-demand video modules and live webinars reviewing a two-tiered approach for implementing key technical and socioadaptive factors to prevent catheter infections, using principles and tools based on the Comprehensive Unit-based Safety Program. CLABSI, CAUTI and catheter use data were collected (preintervention 13 months, intervention 12 months). Multilevel negative binomial models assessed changes in catheter-associated infection rates and catheter use. Of 366 recruited ICUs from 220 hospitals in 16 states and Puerto Rico for two cohorts, 280 ICUs completed the programme including infection outcome reporting; 274 ICUs had complete outcome data for analyses. Statistically significant reductions in adjusted infection rates were not observed (CLABSI incidence rate ratio (IRR)=0.75, 95% CI 0.52 to 1.08, p=0.13; CAUTI IRR=0.79, 95% CI 0.59 to 1.06, p=0.12). Adjusted central line utilisation (IRR=0.97, 95% CI 0.93 to 1.00, p=0.09) and adjusted urinary catheter utilisation were unchanged (IRR=0.98, 95% CI 0.95 to 1.01, p=0.14). This multistate programme targeted ICUs with elevated catheter infection rates, but yielded no statistically significant reduction in CLABSI, CAUTI or catheter utilisation in the first two of six planned cohorts. Improvements in the interventions based on lessons learnt from these initial cohorts are being applied to subsequent cohorts.

Sections du résumé

BACKGROUND
Preventing central line-associated bloodstream infection (CLABSI) and catheter-associated urinary tract infection (CAUTI) remains challenging in intensive care units (ICUs).
OBJECTIVE
The Agency for Healthcare Research and Quality Safety Program for ICUs aimed to reduce CLABSI and CAUTI in units with elevated rates.
METHODS
Invited hospitals had at least one adult ICU with elevated CLABSI or CAUTI rates, defined by a positive cumulative attributable difference metric (CAD >0) in the Centers for Disease Control and Prevention's Targeted Assessment for Prevention strategy. This externally facilitated programme implemented by a national project team and state hospital associations included on-demand video modules and live webinars reviewing a two-tiered approach for implementing key technical and socioadaptive factors to prevent catheter infections, using principles and tools based on the Comprehensive Unit-based Safety Program. CLABSI, CAUTI and catheter use data were collected (preintervention 13 months, intervention 12 months). Multilevel negative binomial models assessed changes in catheter-associated infection rates and catheter use.
RESULTS
Of 366 recruited ICUs from 220 hospitals in 16 states and Puerto Rico for two cohorts, 280 ICUs completed the programme including infection outcome reporting; 274 ICUs had complete outcome data for analyses. Statistically significant reductions in adjusted infection rates were not observed (CLABSI incidence rate ratio (IRR)=0.75, 95% CI 0.52 to 1.08, p=0.13; CAUTI IRR=0.79, 95% CI 0.59 to 1.06, p=0.12). Adjusted central line utilisation (IRR=0.97, 95% CI 0.93 to 1.00, p=0.09) and adjusted urinary catheter utilisation were unchanged (IRR=0.98, 95% CI 0.95 to 1.01, p=0.14).
CONCLUSION
This multistate programme targeted ICUs with elevated catheter infection rates, but yielded no statistically significant reduction in CLABSI, CAUTI or catheter utilisation in the first two of six planned cohorts. Improvements in the interventions based on lessons learnt from these initial cohorts are being applied to subsequent cohorts.

Identifiants

pubmed: 31911543
pii: bmjqs-2019-009330
doi: 10.1136/bmjqs-2019-009330
pmc: PMC7176547
mid: NIHMS1064318
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Pagination

418-429

Subventions

Organisme : AHRQ HHS
ID : K08 HS019767
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: JM has reported receiving honoraria for lectures and teaching related to prevention and value-based policies involving catheter-associated urinary tract infection and hospital-acquired pressure ulcers. SS has reported receiving honoraria for lectures and teaching related to prevention of catheter-associated urinary tract infection, and is on the medical advisory boards of Doximity and Jvion. JM and SS hold a provisional US patent on a technology to improve aseptic placement of urinary catheters, which was not part of this study.

Références

Intensive Care Med. 2004 May;30(5):837-43
pubmed: 15060765
Am J Crit Care. 2006 Nov;15(6):549-55
pubmed: 17053262
Am J Infect Control. 2006 Aug;34(6):388-93
pubmed: 16877109
BMJ Qual Saf. 2018 Oct;27(10):771-780
pubmed: 29950324
Am J Infect Control. 2014 May;42(5):548-50
pubmed: 24576604
J Hosp Infect. 2009 Sep;73(1):41-6
pubmed: 19646788
J Am Coll Surg. 2015 Sep;221(3):739-47
pubmed: 26199017
J Hosp Med. 2017 Nov 8;13(2):105-116
pubmed: 29154382
Jt Comm J Qual Patient Saf. 2009 Sep;35(9):449-55
pubmed: 19769204
Ann Intern Med. 2015 Sep 15;163(6 Suppl):S1-40
pubmed: 26369828
Ann Intern Med. 2009 Jun 16;150(12):877-84
pubmed: 19528567
Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S14-7
pubmed: 20929360
Infect Control Hosp Epidemiol. 2014 Jan;35(1):56-62
pubmed: 24334799
Am J Infect Control. 2015 Jul 1;43(7):711-4
pubmed: 25934065
Ann Intern Med. 2015 May 5;162(9 Suppl):S1-34
pubmed: 25938928
Am J Infect Control. 2016 Oct 1;44(10):1102-1109
pubmed: 27339790
Am J Infect Control. 2014 Jun;42(6):643-8
pubmed: 24837115
Arch Intern Med. 2012 Feb 13;172(3):255-60
pubmed: 22231611
Eur J Anaesthesiol. 2009 Sep;26(9):752-8
pubmed: 19384234
JAMA Intern Med. 2013 May 27;173(10):874-9
pubmed: 23529579
Clin Infect Dis. 2011 Jun;52(11):1291-3
pubmed: 21596672
Infect Control Hosp Epidemiol. 2015 Dec;36(12):1379-84
pubmed: 26310913
Infect Control Hosp Epidemiol. 2010 Apr;31(4):319-26
pubmed: 20156062
Fed Regist. 2011 Jun 6;76(108):32816-38
pubmed: 21644388
MMWR Morb Mortal Wkly Rep. 2011 Mar 4;60(8):243-8
pubmed: 21368740
Public Health Rep. 2007 Mar-Apr;122(2):160-6
pubmed: 17357358
Am J Infect Control. 2011 May;39(4 Suppl 1):S1-34
pubmed: 21511081
Health Care Manag (Frederick). 2015 Jul-Sep;34(3):218-24
pubmed: 26217997
BMJ Qual Saf. 2019 Jan;28(1):74-84
pubmed: 30045864
Am J Infect Control. 2015 Mar 1;43(3):254-9
pubmed: 25728151
N Engl J Med. 2016 Jun 2;374(22):2111-9
pubmed: 27248619
JAMA Intern Med. 2017 Aug 1;177(8):1154-1162
pubmed: 28525923

Auteurs

Jennifer Meddings (J)

Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA meddings@umich.edu.
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Patient Safety Enhancement Program, University of Michigan and VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.

M Todd Greene (MT)

Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Patient Safety Enhancement Program, University of Michigan and VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.

David Ratz (D)

Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
Patient Safety Enhancement Program, University of Michigan and VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.

Jessica Ameling (J)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Patient Safety Enhancement Program, University of Michigan and VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.

Karen E Fowler (KE)

Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
Patient Safety Enhancement Program, University of Michigan and VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.

Andrew J Rolle (AJ)

Health Research & Educational Trust, American Hospital Association, Chicago, Illinois, USA.

Louella Hung (L)

Health Research & Educational Trust, American Hospital Association, Chicago, Illinois, USA.

Sue Collier (S)

Health Research & Educational Trust, American Hospital Association, Chicago, Illinois, USA.

Sanjay Saint (S)

Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Patient Safety Enhancement Program, University of Michigan and VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH